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Abstract
We examined the contribution of serotype on Streptococcus pneumoniae adhesion and virulence during respiratory tract
infection using a panel of isogenic TIGR4 (serotype 4) mutants expressing the capsule types 6A (+6A), 7F (+7F) and 23F
(+23F) as well as a deleted and restored serotype 4 (+4) control strain. Immunoblots, bacterial capture assays with
immobilized antibody, and measurement of mean fluorescent intensity by flow cytometry following incubation of bacteria
with antibody, all determined that the surface accessibility, but not total protein levels, of the virulence determinants
Pneumococcal surface protein A (PspA), Choline binding protein A (CbpA), and Pneumococcal serine-rich repeat protein
(PsrP) changed with serotype. In vitro, bacterial adhesion to Detroit 562 pharyngeal or A549 lung epithelial cells was
modestly but significantly altered for +6A, +7F and +23F. In a mouse model of nasopharyngeal colonization, the number of
+6A, +7F, and +23F pneumococci in the nasopharynx was reduced 10 to 100-fold versus +4; notably, only mice challenged
with +4 developed bacteremia. Intratracheal challenge of mice confirmed that capsule switch strains were highly attenuated
for virulence. Compared to +4, the +6A, +7F, and +23F strains were rapidly cleared from the lungs and were not detected in
the blood. In mice challenged intraperitoneally, a marked reduction in bacterial blood titers was observed for those
challenged with +6A and +7F versus +4 and +23F was undetectable. These findings show that serotype impacts the
accessibility of surface adhesins and, in particular, affects virulence within the respiratory tract. They highlight the complex
interplay between capsule and protein virulence determinants.
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Introduction
Capsular polysaccharide (capsule) is the most important
virulence determinant of Streptococcus pneumoniae, surrounding and
protecting the bacterium against complement-mediated phagocy-
tosis and bacterial killing by extracellular traps [1,2,3,4]. The
requirement for capsule is made evident by the fact that all
invasive clinical isolates of S. pneumoniae are encapsulated [5],
unencapsulated pneumococci are incapable of causing pneumonia
or sepsis in animal models [6,7], and antibodies against capsule
promote opsonization and confer protection [8,9]. Indeed,
purified capsule serves as the protective antigen in all vaccines
approved worldwide against S. pneumoniae.
Although capsule affords protection against host-clearance, it
also hinders the ability of the pneumococcus to adhere to host
epithelial cells [10,11]. This is likely due to a blocking of bacterial
adhesins by the capsule that prevents their interaction with
host ligands. To compensate, the pneumococcus spontaneously
undergoes phase variation, alternating between a transparent
low-capsule phenotype which is adhesive to host cells but subject
to opsonophagocytosis, and an opaque high-capsule phenotype
that is resistant to opsonophagocytosis but less able to attach to
cells [12]. Additionally, some pneumococci carry Pneumococcal
serine-rich repeat protein (PsrP), a member of the serine-rich
repeat protein family, or pili, that are thought to extend outward
through the capsule and mediate adhesion even in the presence of
capsule [13,14,15,16,17]. Finally, studies using scanning electron
microscopy suggest that the pneumococcus actively down-
regulates capsule production when attached to epithelial cells
[11]. Thus, the presence of capsule profoundly affects how the
pneumococcus interacts with host epithelial cells and not just
phagocytes.
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capsule types of S. pneumoniae have been described. Importantly,
not all serotypes are equally capable of colonizing the nasopharynx
or causing invasive disease. For example, in the United States only
13 serotypes (i.e. 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and
23F) are responsible for 80–90%of invasive pneumococcal
infections [18,19,20]. The reasons for why some serotypes are
more likely to cause disease remain unclear, as pneumococci are
genetically diverse and non-invasive clones belonging to these
disease-associated capsule types have also been described [21,22].
Thus the only way to assess the individual contribution of capsule
type to virulence is to compare isogenic capsule-switched strains of
the same genetic background.
In 1994, studies by Kelly et al. showed that isogenic changes in
capsule type unpredictably altered virulence following intraperito-
neal challenge. Replacement of capsule type 5 on a highly virulent
strain with type 3 resulted in a complete loss of virulence. In
contrast, change of a non-virulent serotype 6A strain to capsule type
3 enhanced virulence [23]. One proposed explanation for this was
that capsule type affected resistance to both complement deposition
and opsophagocytic uptake. In support of this notion, recent studies
haveshown that the switching of a serotype 4 isolate to serotype 23F
or 6A increased C3b deposition and phagocytic uptake, whereas
replacement with 7F had a minimal effect [24]; similar results have
been reported by Melin et al. [25,26,27]. Importantly, differences in
C3b deposition on the bacterial surface have been suggested to be
due, in part, to differences in the surface exposure of pneumococcal
proteins with anti-complement activity such as Choline binding
protein A (CbpA), which binds to Factor H and is an adhesin for
laminin receptor and the polymeric immunoglobulin receptor
[28,29,30], and Pneumococcal surface protein A (PspA), which
inhibits complement deposition by unknown mechanisms [31]. For
example, replacement of strain D39 serotype 2 capsule with
serotype 3 reduced the reactivity of antisera against PspA [32].
Thus, interplay between capsule and surface exposed virulence
determinants most likely occurs and impacts virulence potential.
Herein, using isogenic mutants, we tested whether capsule type
also impacts pneumococcal adhesion and virulence at sites where
bacterial attachment is required. We determined that changes in
capsule altered surface accessibility of the pneumococcal adhesins
PsrP and CbpA as well as PspA, modulated bacterial adhesion in
vitro, and attenuated nasopharyngeal colonization and virulence
within the lungs. These studies provide insight into the complex
interplay between capsule and bacterial surface components and
help explain why not all combinations are compatible for virulence.
Methods
Bacterial strains and tissue culture cell lines used
The isogenic capsule switch opaque phase variant mutants were
kindly provided as a gift by Dr. Jeffery Weiser at The University of
Pennsylvania and were generated using a Janus cassette [24]. S.
pneumoniae serotype 4, strain TIGR4 was used as the background
strain [21,33]. The capsule switch strains include TIGR4
derivatives expressing the 6A (+6A), 7F (+7F), and 23F (+23F)
capsule type as well as a deleted and restored capsule type 4 (+4).
The latter served as the control for the panel of isogenic mutants.
Previously, we have shown that +6A, +7F, and +23F carry
equivalent amounts of capsule as +4 and have comparable growth
rates in Todd Hewitt Broth (THB) and serum [24]. An
unencapsulated derivative of TIGR4, T4R, was also used as a
negative control [34]. Unless otherwise indicated, pneumococci
were grown on tryptic soy blood agar plates (Remel, USA) or THB
at 37uC in 5%CO2.
Confirmation of appropriate capsule production by
switch mutants
Multiplex PCR using genomic DNA as template and serotype
specific primers was performed to verify the presence of specific
capsule type genes in each strain [35,36]. Production of the correct
polysaccharide capsule was confirmed by agglutination using type-
specific antibodies (Statens Serum Institut, Denmark).
Assessment of surface accessibility of the pneumococcal
adhesins on antibody- immobilized surfaces
Polystyrene 24-well plates were coated with rabbit polyclonal
antibodies against CbpA and PsrP (1:250 in PBS) overnight.
Serum from a naı ¨ve animal was used as a negative control.
Bacterial cultures were diluted in phosphate buffered saline (PBS)
to an OD620 of 0.1, and incubated for 1 h at 37uC on the antibody
coated wells. Following incubation, wells were gently washed 3
times with PBS to remove unbound bacteria and attached bacteria
were freed with gentle scraping. Bacterial adhesion was deter-
mined by addition of 100 ml PBS, plating of the bacterial
suspension, and extrapolation from colony counts following
overnight incubation. Each experiment contained at least 3
biological replicates for each strain tested.
Detection of surface expression of pneumococcal
proteins by flow cytometry
Indirect immunofluorescence was carried out to determine the
ability of antibodies against recombinant CbpA, PsrP and PspA
to bind to the surface of intact S. pneumoniae (17). Antibodies
against PsrP were previously generated [13,37], whereas those
against CbpA where a kind gift from Dr. Elaine Tuomanen
(Memphis, TN). Antibodies against PspA were obtained from
Santa Cruz Biotechnology (sc-17483, Santa Cruz, CA). Con-
firmed opaque pneumococci were harvested directly from blood
agar plates grown overnight or from exponential growth phase
liquid cultures (Optical Density [OD]620=0.5), washed in sterile
PBS and suspended in staining buffer (0.05% sodium azide and
1% bovine serum albumin in PBS). Approximately 2610
7
bacteria were incubated with 10% rabbit antisera to CbpA or
PsrP or with 10% goat antiserum to PspA. As a control rabbit
and goat IgG isotypes were used (Sigma Aldrich, St. Louis MO).
Following incubation at 4uC for 1 h, bacteria were washed and
incubated with a 1:100 dilution of a F(ab’)2 fragment of goat anti-
rabbit IgG (H+L) or donkey anti-goat conjugated to Phycoery-
thrin (Jackson Immunoresearch Laboratories, Westgrove PA).
Bacteria were washed in PBS and subjected to flow cytometry
using a Becton Dickinson LSR-II flow cytometer using forwards
and side scatter parameters to gate on at least 10,000 bacteria.
Results were analyzed using FlowJo v9.3 software (Becton
Dickinson) and the data is presented as mean fluorescence
intensity (MFI) and as the percent of the bacterial population
positive for relative markers.
Bacterial Adhesion Assays
A549 (human lung alveolar epithelium cell line; ATCC CRL-
185) and Detroit 562 (human nasopharyngeal epithelial cells;
ATCC CCL-138) were maintained in either F-12 media
supplemented with 10% fetal bovine serum or MEM media
supplemented with 10% FBS, 10% lactoalbumin hydrolate, and 2
mM L-glutamine, respectively. All cell lines were maintained at
37uCi n5 %C O 2. Adhesion assays were performed as previously
described [37]. Cells were grown to 90–95% confluence (,10
6
cells/well) in 24-well tissue culture polystyrene plates. Cells were
washed then exposed to media containing 10
7 CFU/ml of
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were removed by washing the cells 3 times with PBS. Adherent
bacteria were quantitated by lysis of the cell monolayer with 0.1%
Triton X-100 in PBS, serial dilution of the lysate followed by
plating on blood agar plates, and extrapolation from colony counts
the next day. Each experiment contained at least 3 biological
replicates for each strain tested.
Virulence studies in mice
Challenge experiments described below were performed at
the University of Texas Health Science Center at San Antonio
using an Institutional Animal Care and Use Committee
approved protocol 09022-34. To minimize distress mice were
anesthetized during experimental challenge and prior to
euthanasia. Five-week-old, female, BALB/cJ mice (The Jackson
Laboratories, Bar Harbor, ME) were anesthetized with 2.5%
vaporized isoflurane. We have previously used BALB/c mice to
determine the anatomical site-specific contribution of numerous
pneumococcal virulence determinants including PsrP and CbpA
[30,37,38].
The intranasal, intratracheal, and intraperitoneal challenge
models have been previously described [37]. For intranasal
challenge, anesthetized mice were held upright and 10
6 CFU of
S. pneumoniae in 25 ml PBS was administered into the left nostril in
a drop-wise fashion. For intratracheal challenge, anesthetized
mice were hung upright by their incisors and 10
5 CFU of S.
pneumoniae in 100 mL of PBS was placed at the back of the throat.
Forced aspiration was induced by gently pulling the tongue
outward and covering the nostrils. For intraperitoneal challenge
mice were injected with 10
4 CFU in 100 ml PBS. On designated
days, nasopharyngeal lavage with 10 ml saline or collection of
blood from the tail vein was performed. Nasopharyngeal lavage
was performed by drop-wise instillation of PBS and recovery
from the same nostril after a few seconds. Bacterial titers in the
nasopharynx and blood, respectively, were determined by serial
dilution, plating, and extrapolation from colony counts the next
day. For determination of bacterial titers in the lungs, mice were
sacrificed, the lungs excised, weighed, and homogenized in PBS.
Bacterial burden in the lungs was assessed per gram of
homogenized tissue.
Figure 1. Differences in surface expression of pneumococcal ligands is dependent on serotype. A) Immunoblot analysis comparing
relative protein levels in whole cell lysates of TIGR4, an unencapsulated derivate (T4R), and the panel of capsular switch mutants. Whole cell lysates
(10 mg) were separated by 12%SDS-PAGE and transferred to nitrocellulose or directly blotted onto membranes and probed with antisera to choline
binding protein (CbpA), pneumococcal surface protein A (PspA), or the pneumococcal serine-rich repeat protein (PsrP). B) Capture of bacteria to
immobilized antibodies to CbpA (black bars) and PsrP (white bars). TIGR4 and the panel of isogenic mutants were incubated in wells pre-coated with
serum to CbpA or PsrP and surface expression was indicated by the amount of bacteria captured to immobilized antibody. Values are presented as a
percentage of capture of the TIGR4 strain. Statistical analysis was performed using a two-tailed Student’s t-test versus TIGR4. Single asterisk indicates
P,0.05, double asterisks indicates P,0.001.
doi:10.1371/journal.pone.0026587.g001
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University College London under Home Office license PPL70/
6510. Animal experiments were also approved by the University
College London Biological Service Unit Ethics Committee. Sex-
matched 6 week old CD1 mice were inoculated intranasally under
halothane anesthesia with 10
7 CFU FAM-SE labeled S. pneumoniae.
Mice were sacrificed after 4 hours and bronchoalveolar lavage
fluid (BALF) collected using an angiocatheter and flushing of the
lungs with 1 ml sterile PBS (35). Bacterial CFU were calculated by
plating serial dilutions of BALF. S. pneumoniae phagocytosis by
BALF AMs was analyzed using a FacsCalibur (Becton Dickinson)
to identify the proportion of cells associated with fluorescent
bacteria.
Statistical analysis
For statistical comparisons between 2 cohorts a two-tailed un-
paired Student’s t-test was used. For comparisons between
multiple cohorts a One-Way ANOVA or Dunn’s Multiple
Comparison test was used. Statistical analyses were performed
using SigmaStat software (Systat Software, Chicago IL).
Results
Levels of CbpA, PsrP and PspA were unaffected by
changes in serotype
Prior to experimentation, +6A, +7F, +23F and +4 were
confirmed to produce the appropriate capsule type by multiplex
PCR for serotype specific genes as well as agglutination with
serotype specific antiserum (Figure S1). Additionally, we assessed
whether switching capsule impacted production of proteins. As
determined by immunoblot analysis, +6A, +7F, +23F, had
equivalent total levels of CbpA, which binds to Laminin receptor
and Polymeric immunoglobulin receptor [29,30], PsrP, which
binds to Keratin 10 [13], and PspA, which inhibits complement
Figure 2. Effect of serotype and surface accessibility of pneumococcal ligands. Flow cytometry histograms for pneumococcal surface
ligands CbpA, PspA, and PsrP in A) TIGR4 and its unencapsulated derivative (T4R) and B) the isogenic capsular switch strains +4, +6A, +7F, +23F.
Histograms are representative of three independent experiments using bacteria collected from overnight plates (similar results were obtained using
planktonic pneumococci). Surface accessibility of CbpA, PspA, and PsrP as measured by mean fluorescence intensity (MFI; black bars) and %PE+
positively labeled cells (white bars). Results from three independent experiments are shown. Statistical analysis was performed using a two-tailed
Student’s t-test versus T4. Single cross indicates P,0.05, double cross indicates P,0.001.
doi:10.1371/journal.pone.0026587.g002
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lated TIGR4 derivative (Figure 1A).
Surface accessibility of pneumococcal ligands is
dependent on serotype
Using polystyrene plates coated with antibody specific for either
CbpA or PsrP, we first determined that +6A, +7F, and +23F had a
dramatic reduction in their ability to be captured on a flat surface
versus +4. In contrast, +4 was captured at levels equivalent to
TIGR4, and T4R showed enhanced retention (Figure 1B). As the
antibody was immobilized, and therefore unable to penetrate the
capsule layer, this experiment modeled the ability of these adhesins
to bind to their ligand on the host cell surface.
We also compared the ability of free labeled-antibody to bind to
CbpA, PsrP, and PspA on the bacterial surface using flow
cytometry. Compared to TIGR4, T4R had significantly increased
mean fluorescent intensity (MFI) demonstrating that capsule
blocked antibody access to these surface proteins (Figure 2A, C).
Compared to +4, the capsule switch strains +6A, +7F, and +23F
also had reduced accessibility to antibody as determined by MFI
and the detected percentage of PE+ cells (Figure 2B,C). This
remained constant whether bacteria were collected from overnight
blood agar plates (Figure 2) or from logarithmic growth phase
liquid cultures (data not shown). Thus, changes in serotype
reduced surface accessibility of CbpA, PsrP and PspA on the
bacteria outer surface to immobilized and free antibody.
Effect of capsule type on bacterial adhesion in vitro
To assess whether changes in surface accessibility of CbpA and
PsrP altered bacterial adhesion in vitro, we examined the ability of
the capsule switch strains to adhere to Detroit 562 cells, a human
nasopharyngeal cell line, and A549 cells, a type II pneumocyte cell
line (Figure 3). Strain +4, the capsule switch control strain,
adhered to monolayers of both cell lines at levels equivalent to
TIGR4. In contrast, +6A adhered to Detroit 562 and A549 cells at
levels slightly greater and lower than +4, respectively. +7F
demonstrated a moderately enhanced capacity to adhere to these
cells; a 1.5 and 1.7-fold increase in adhesion was observed versus
+4, respectively. Finally, +23F had a less than 2-fold reduction in
its ability to adhere to Detroit 562 cells but not A549 cells. Thus
changes in capsule type resulted in unexceptional but reproducible
changes in bacterial adhesion in vitro that were capsule type and
host cell type dependent.
Capsule type affects nasopharyngeal colonization and
virulence potential
Having observed discrepant results in regards to the impact of
serotype switch on bacterial antibody capture and cell adhesion,
we tested the effect of changing capsule type on nasopharyngeal
colonization and subsequent development of pneumonia; infec-
tious disease states that have previously been shown to require
CbpA and PsrP [37,38]. Importantly, the +4 control strain was
found to be modestly attenuated compared to the TIGR4 strain in
the intransal and intraperitoneal experiments (Figure 4A, 5B).
Thus, insertion of the Janus cassette had inadvertent consequences
and only comparisons between the +6A, +7F, and +23F versus +4
are valid.
Following intranasal challenge, +6A, +7F, and +23F had
significantly reduced median bacterial titers in the nasopharynx
versus +4 as early as 24 h post-infection and continuing up to 120
h (Figure 4A). For +6A a 100-fold reduction in median bacterial
titers was observed after 120 h. Surprisingly, only +4 caused
bacteremia following intranasal challenge (Figure 4B). At no time
were +6A, +7F, or +23F detected in the bloodstream of challenged
mice. Thus the capsule switch strains were moderately attenuated
in their ability to colonize the nasopharynx but completely unable
to cause invasive disease following intranasal challenge.
To dissect how capsule type might be affecting disease
progression, we subsequently infected mice intratracheally and
intraperitoneally (Figure 5). Mice infected intratracheally with
10
5 CFU of the +6A, +7F, and +23F capsule switch strains had no
bacteria in their lungs or blood at any time tested. In contrast,
mice infected with +4 strain developed low-grade pneumonia and
bacteremia that was comparable to wild type (Figure 5A).
Following intraperitoneal challenge, +6A, +7F were capable of
persisting within the blood at lower levels than +4, whereas +23F
was immediately cleared (Figure 5B). Thus, changes in capsule
type had a strong attenuating affect within the lungs that
precluded entry of +6A, +7F into the bloodstream, and +23F
was attenuated in all anatomical sites tested.
Figure 3. Effect of serotype on bacterial adhesion. In vitro adhesion assays measuring the ability of TIGR4 or the isogenic capsular switch mutants
to adhereto A) humanlung alveolar (A549)andB) nasopharyngeal(Detroit) cell lines.Adhesionis expressedas a percentage relative to TIGR4 adhesion.
Statistical analysis was performed using a two-tailed Student’s t-test versus TIGR4. Single asterisk indicates P,0.05, double asterisks indicates P,0.001.
doi:10.1371/journal.pone.0026587.g003
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Within the lungs, establishment of pneumococcal pneumonia
is dependent on both the ability of the bacteria to attach to cells,
yet remain resistant to phagocytosis by resident alveolar
macrophages. To investigate whether effects on macrophage-
mediated immunity might also explain the strong attenuation of
the capsule switch strains in the lungs, mice were inoculated
with fluorescent S. pneumoniae strains and bacterial uptake by
alveolar macrophages assessed 4 hours after inoculation using
flow cytometry. The association of alveolar macrophages with
+6A and +23F strains was increased compared to the +4 strain,
whereas the association of the +7F strain was similar (Figure 6A).
Bacterial CFU in the BALF was consistent with these results,
with significantly fewer bacterial CFU for the +6A and +23F
but not the +7F compared to +4 in BALF 4 hours after
inoculation (Figure 6B). Hence, serotype 6A and 23F increased
uptake of S. pneumoniae by alveolar macrophages and the rate of
bacterial clearance from the lung, whereas capsule type 7F had
no effect.
Discussion
While considerable work has been done to examine the effect of
capsule type on complement deposition and the effect of serotype
on the ability of pneumococci to colonize the nasopharynx and
survive in bloodstream [4,24,26,27,28,40,41], this is the first study
to assess the impact of capsule type on bacterial adhesin function
and the development of pneumonia. Given that pneumonia is the
most common serious disease presentation caused by the
pneumococcus and host-cell adhesion is a requisite event for
development of invasive disease [15,29,37,38,42], our study begins
to address this important lapse in our understanding of S.
pneumoniae pathogenesis.
The most studied feature of the pneumococcal capsule is its
inhibitory effect on opsonization and phagocytosis. In regards to
the latter, using the same isogenic capsule switch strains, we and
others have shown that capsule type impacts the amount of C3b
that is deposited on the bacteria surface and subsequent uptake by
neutrophils [4,24,25,26,27]. Our current findings suggest that the
Figure 4. Genetic switch of serotype alters nasopharyngeal colonization and virulence in mice. Bacterial titers were measured for
individual 5-week old female BALB/cJ mice intranasally infected with 10
6 CFU of the parental TIGR4 WT (n=8) or the isogenic capsular switch strains
+6A, +7F, +23F, and +4 (n=6). A) Nasal lavages and B) blood were collected at 24, 72, and 120 h post-infection. Horizontal bars represent the median
value. Statistical analysis was performed using One-Way ANOVA in comparison to both the TIGR4 strain (*) and the internal +4 control strain (+).
Asterisk and the cross indicate a significance value of P,0.05.
doi:10.1371/journal.pone.0026587.g004
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particular PsrP and CbpA function. In support of this notion, we
observed reduced capture of intact bacteria by immobilized
antibody against PsrP and CbpA in the +6A, +7F, and +23F
capsule switch strains versus +4, altered accessibility of free-
antibody to these adhesins and to PspA by flow cytometry, and a
stronger attenuation for +6A and +7F in the lungs versus the
blood. In the lungs the pneumococcus requires both bacterial
attachment and resistance to opsonophagocytosis in order to
persist. The combination of these two factors may explain the
different effects of serotype on virulence between pneumonia and
sepsis models.
Pneumococcal adhesion is dependent on the ability of bacterial
proteins to interact with ligands on the host cell surface. The
presence of capsule is known to negatively impact these
interactions, thus investigators routinely use unencapsulated
pneumococci when examining the role of their selected adhesins
[42,43,44]. Our in vitro finding that capsule type impacted the
ability of immobilized antibody against CbpA and PsrP to capture
pneumococci suggests that the biochemical properties of these
capsule types alters their exposure on the outer surface of the
pneumococcus. Results from our cytometric analyses support this
notion and showed that the presence of capsule decreased the
ability of free antibody against PspA, CbpA, and PsrP to gain
access to these proteins, and that capsule types 6A, 7F, and 23F
permitted less accessibility that capsule type 4. Notably, PsrP and
CbpA deficient mutants have been demonstrated to be more
severely attenuated in the lungs rather than bloodstream of
experimentally infected mice [37,38]. Thus, the observed impact
of diminished CbpA and PsrP exposure by +6A, +7F, and +23F
versus +4, is consistent with past and present experimental
observations in vivo.
Importantly, the modest reduction observed for only +23F in
the in vitro bacterial adhesion assays is difficult to reconcile with our
data showing reduced surface accessibility of CbpA and PsrP. This
discrepancy may be because the pneumococcus uses multiple
Figure 5. Serotype affects virulence in the lungs. Bacterial titers were measured for individual 5-week old female BALB/cJ mice infected via A)
intratracheal (10
5 CFU) or B) intraperitoneal (10
4 CFU) routes with TIGR4 WT (n=6) or the isogenic capsular switch strains +6A, +7F, +23F, and +4
(n=6). For intratracheal challenge samples were collected at 48 h post-infection, and for intraperitoneal challenge samples were collected at 24 and
48 hours. Horizontal bars represent the median value. Statistical analysis was performed using One-Way ANOVA in comparison to both the TIGR4
strain (*) and the internal +4 control strain (+). Asterisk and the cross indicate a significance value of P,0.05.
doi:10.1371/journal.pone.0026587.g005
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compensated. For example, the pneumococcus also binds to
epithelial cells through phosphorylcholine residues on its cell wall,
with the tip of a pilus structure, using the MSCRAMMs (Microbial
Surface Components Recognizing Adhesive Matrix Molecules)
PavA and PavB, and with a multitude of normally cytoplasmic
enzymes that decorate the bacterial surface, among others
[45,46,47]. If this compensatory effect were to hold true in vivo,
the observed dramatic attenuation of the isogenic switch strains in
the lungs would therefore have to be the result of capsule-mediated
changes in the secondary function of surface proteins. While we
did not explore this possibility, CbpA has been shown to bind to
Factor H and further inhibit complement deposition [48].
Likewise, PsrP also mediates in vivo biofilm formation [49]. Thus
altered function on top of reduced accessibility may explain the
discrepancy between cell adhesion assays and virulence.
CbpA, PspA, and PsrP are highly variable and show strong
associations with clonotype and/or capsular type. For example
numerous isotypes of CbpA exists with alterations in the R1 and
R2 domains of the protein [50]. Similarly, the protein PspA is
classified into two major families depending on its amino acid
composition [31]. Sequence analysis of the published genomes
indicates that PsrP also demonstrates considerable variability, in
particular the length of its SRR2 domain that serves to extend the
protein outward [13]. The observed difference in the surface
accessibility of these proteins and their known structural variability
raises the possibility that some versions of CbpA and PsrP might
only be compatible with certain serotypes. Perhaps invasive clones
of each serotype carry the optimized version of these proteins for
the corresponding serotype. This would perhaps help explain why
certain virulence determinants such as PsrP are not equally
distributed among serotypes [17]. Interestingly, in the MFI
experiments with the capsule switch strains and free antibody
(Figure 2B), we observed that some of the graphs had what might
be construed as two distinct cell populations (e.g. PspA). As we
used confirmed opaque bacteria, we could exclude phase-variation
as the cause of this bimodality. Furthermore, as we saw similar
results following experiments with overnight cultures and plank-
tonic cultures, we could exclude the presence of dead cells. The
cause for this phenomena remains unknown, albeit for the
pneumococcal pilus a non-phase variable bimodilty has been
recently described [51].
Finally, we have previously demonstrated that complement
activity was maximum against +6A and +23F, followed by +7F,
and then +4 [24]; and this was reflected in our current
experiments examining bacterial uptake by resident alveolar
macrophages in the lungs, measurement of bacterial titers in the
bronchoalveolar lavage fluid, and after intraperitoneal inoculation
where mice challenged with +6A, +7F, and +23F had significantly
lower numbers of pneumococci in their blood than those
challenged with +4. Thus any effects of capsule on CbpA and
PsrP function are concomitant with those that occur in regards to
opsonophagocytosis.
Importantly, all the strains used in this study were of the
opaque phase variation, had similar capsule thickness, and
showed equivalent growth rates in vitro [24]. While we were
surprised to observe that the +4 strain was attenuated in vivo in
comparison to wild type TIGR4, suggesting an inadvertent affect
of the Janus insertion or another mutation incurred during
creation, the fact that we only compared +6A, +7F, +23F to +4i n
these studies allowed for its control. Thus the observed differences
can be attributed to the biological properties of the serotype and
not the relative fitness or amount of capsule surrounding the
bacterium.
Taken together our findings indicate that there is complex
relationship between capsular and non-capsular determinants that
synergistically effect virulence potential, particularly in the lungs.
Based on our findings and those of other investigators, we propose
that the capsular type imposes a biochemical threshold for surface
accessibility/functionality of proteins which must be overcome by
altered or enhanced expression of other genetic determinants. As a
result, certain genetic backgrounds (i.e. clonotypes) are better
suited for certain serotypes versus others. We speculate that this
explains why certain forms of proteins are expressed in specific
capsular type backgrounds, moreover, why we observed that
replacement of capsular type can have a profound effect on
virulence independent of strain background.
Supporting Information
Figure S1 Confirmation of expression of capsule types
by the capsular switch strains. A) Appropriate capsular
serotype production was confirmed for the switch strains by a
series of five different PCR reactions which amplified serotype-
specific genes for capsule type 4, 6A, 7F, and 23F as well as cpsA
(positive control). B) Agglutination assay using serotype specific
antiserum confirmed production of capsule types by the capsule
switch mutants.
(EPS)
Figure 6. Clearance of FAMSE-labeled capsule switch strains
from the lungs and uptake by alveolar macrophages 4 hours-
post inoculation. A) Alveolar macrophage phagocytosis of CPS
switch strains as determined by FACS. Data presented as the median
(IQR) fluorescence index (percentage of fluorescent macrophages
multiplied by the geo mean MFI) for BALF macrophages (n=5). B)
Median bacterial titers in bronchoalveolar lavage fluid (BALF) (n=5). For
panels A and B samples were collected 4 hours after intranasal
challenge with 5610
6 CFU FAMSE-labeled CFU, and the P values given
above the respective box and whisker plot for individual strains are for
comparison to the +4 strain. A Dunn’s Multiple Comparison test was
used for statistical analyses.
doi:10.1371/journal.pone.0026587.g006
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